PAVM PAVmed Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1624326 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY410.3%
TTM net income YoY-693.3%
TTM EPS YoY—
Revenue 3-yr CAGR-54.7%
Net income 3-yr CAGR—
Margins
Gross margin-212.2%
Operating margin-19,315.5%
Net margin-12,406.8%
FCF margin-3,024.3%
EBITDA margin-19,264.2%
Returns
ROE-61.2%
ROA-50.1%
ROIC (approx.)-84.8%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets71.2%
Debt / equity0.00x
Current ratio0.41x
Interest coverage-5,717.40x
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-38.1%
Payout ratio—
Capex / revenue38.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $71,000 | $3.00M |
| Cost of revenue | $218,000 | $4.84M |
| Gross profit | -$147,000 | -$1.84M |
| R&D expense | $4.49M | $5.93M |
| SG&A expense | $16.25M | $24.52M |
| Operating income | -$21.81M | -$44.49M |
| Interest expense | $21,000 | $45,000 |
| Pretax income | -$2.47M | $28.43M |
| Income tax | $0 | $0 |
| Net income | $401,000 | $39.79M |
| EBITDA | -$21.70M | -$43.29M |
| EPS (basic) | -5.63 | 99.15 |
| EPS (diluted) | -5.63 | 14.90 |
| Weighted avg. shares (diluted) | 670,466 | 2.17M |
| Balance sheet | ||
| Cash & equivalents | $1.24M | $1.19M |
| Receivables | $15,000 | $18,000 |
| Current assets | $2.26M | $2.16M |
| PP&E, net | $77,000 | $151,000 |
| Total assets | $38.81M | $30.66M |
| Current liabilities | $14.84M | $35.45M |
| Total liabilities | $16.51M | $37.69M |
| Shareholders' equity | $33.97M | -$2.50M |
| Shares outstanding | 927,934 | 373,300 |
| Cash flow statement | ||
| Operating cash flow | -$5.21M | -$33.55M |
| Capital expenditure | $31,000 | $55,000 |
| Free cash flow | -$5.24M | -$33.61M |
| Investing cash flow | -$31,000 | -$16.18M |
| Financing cash flow | $5.59M | $31.28M |
| Depreciation & amortization | $105,000 | $1.20M |
| Stock-based compensation | $1.71M | $6.45M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.